Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.
TTFields Plus SOC Provides Survival Advantage for Patients With Stage IV NSCLCJanuary 5th 2023
The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.
Ripretinib Shows Better Efficacy Than Sunitinib in Imatinib-Pretreated Patients With KIT-Mutated GISTJanuary 5th 2023
INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.
FDA Decision on Toripalimab for Advanced Nasopharyngeal Carcinoma Pending Due COVID-19 Travel RestrictionsDecember 24th 2022
The FDA has not made a decision on the approval application for toripalimab plus chemotherapy or toripalimab monotherapy for the treatment of advanced recurrent or metastatic nasopharyngeal carcinoma.
Bringing Targeted Agents from Clinical Trials to the Clinic for Patients With Uterine SarcomaDecember 23rd 2022
In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.
Datopotamab Deruxtecan Shows Durable Efficacy and Manageable Safety in HR+/HER2- Breast CancerDecember 15th 2022
Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.
HD-ASCT Shows Longer Survival Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS LymphomaDecember 13th 2022
An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Belantamb Mafodotin Shows PFS Benefit and Tolerable Safety in R/R Multiple MyelomaDecember 12th 2022
Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.
Ribociclib Plus ET Yields 46% Reduction in Disease Progression in Pre/Perimenopausal HR+/HR- Advanced Breast CancerDecember 6th 2022
Yielding a 46% reduction in the risk of disease progression of death compared with combination chemotherapy, ribociclib plus endocrine therapy may be a new standard of care for patients with pre/perimenopausal HR-positive, HER2-negative advanced breast cancer
Dostarlimab Achieves Significant PFS Improvement in Primary Advanced or Recurrent Endometrial CancerDecember 2nd 2022
The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.
FDA Grants FTD to Pelareorep Plus Atezolizumab and Chemotherapy for Advanced PDACDecember 2nd 2022
The FDA has granted a fast track designation to the combination of pelareorep and atezolizumab with gemcitabine and nab-paclitaxel for advanced or metastatic pancreatic ductal adenocarcinoma after promising results were presented from the GOBLET study at the SITC Annual Meeting.
FDA Approves Olutasidenib for Relapsed/Refractory IDH1+ Acute Myeloid LeukemiaDecember 2nd 2022
Positive and durable complete responses observed with olutasidenib in adult patient with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation have led the FDA to grant approval to the drug for this group of patients
Pembrolizumab Combo Prolongs Survival in HER2–, Locally Advanced Unresectable or Metastatic Gastric/GEJ CancersNovember 22nd 2022
Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.
FDA Grants Priority Review to Subcutaneous Epcoritamab for Previously Treated R/R LBCLNovember 21st 2022
Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.
Trilaciclib Shows Potential to Lower Chemotherapy-Induced Myelosuppression Episodes in ES-SCLCNovember 18th 2022
Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of patients with extensive-stage small cell lung cancer experiencing chemotherapy-induced myelosuppression events.